Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Proposes Add’l Conditions for Penalty Medical Fee Cuts: Chuikyo
January 11, 2018
- Balancing Innovation and Universal Coverage Was Key in Drug Pricing Reform: Health Minister
January 10, 2018
- PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive
January 9, 2018
- MHLW Unofficially Notified Companies of Products Eligible for New PMP: Sources
January 9, 2018
- MHLW Study Group Approves Framework for Comprehensive Guidelines on Pharmacotherapy in the Elderly
January 9, 2018
- Counterfeit Drug Panel OKs Final Report, MHLW to Issue GDP Guidelines in FY2018
December 27, 2017
- Council OKs Public Knowledge-Based Application for Diagnogreen, Valixa
December 26, 2017
- MHLW OKs Add’l Indications for Keytruda, Soliris and More
December 26, 2017
- Japan Cabinet OKs FY2018 Budget, 52.9 Billion Yen Earmarked for Urgent Drug Discovery Package
December 25, 2017
- “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market
December 25, 2017
- Single Price Band Rule for Generics to Get Underway in April 2020: MHLW
December 22, 2017
- Mogamulizumab Gets Orphan Status for HTLV-1-Associated Myelopathy
December 22, 2017
- Chuikyo Wraps Up CEA Debate for This Year, Sorts Out Issues towards Full Rollout
December 22, 2017
- 4th or Later Players Could Also Qualify for PMP If Post-Launch “True Clinical Utility” Premium Granted: MHLW
December 21, 2017
- Outline of Drug Pricing Reform Package
December 21, 2017
- Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
- (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
- Meiji-Kumamoto JV Becomes “Company that Can Succeed Worldwide”: Kaketsuken Chief
December 19, 2017
- MHLW Approves Proposed Reforms to Allow the Export of Plasma Fraction Products
December 19, 2017
- Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…